Treatment of functional diarrhea

Current Treatment Options in Gastroenterology

Volumn 9, Issue 4, 2006, Pages 331-342

  Dellon, Evan S ^b   Ringel, Yehuda ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; ATROPINE; ATROPINE PLUS DIPHENOXYLATE; BENZODIAZEPINE; BISMUTH; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILANSETRON; CIPROFLOXACIN; COLESTIPOL; COLESTYRAMINE; DESIPRAMINE; DICYCLOVERINE; DIPHENOXYLATE; GENERIC DRUG; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; IMIPRAMINE; LOPERAMIDE; MESALAZINE; METHYLSCOPOLAMINE; METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; SOMATOSTATIN DERIVATIVE; SPASMOLYTIC AGENT; TETRACYCLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANTICHOLINERGIC SYNDROME; ANXIETY; BACTERIAL OVERGROWTH; BEHAVIOR THERAPY; BILE DUCT DISEASE; BLOATING; BLOOD BRAIN BARRIER; BLURRED VISION; BRADYCARDIA; CARBOHYDRATE INTOLERANCE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHOLECYSTECTOMY; CLINICAL TRIAL; COGNITIVE THERAPY; COLONOSCOPY; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY FIBER; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FECES INCONTINENCE; FLUSHING; FUNCTIONAL DIARRHEA; GASTROINTESTINAL SYMPTOM; GIARDIASIS; HALLUCINATION; HEALTH CARE COST; HEART ARRHYTHMIA; HEART PALPITATION; HEARTBURN; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFORMED CONSENT; INJECTION SITE REACTION; INTESTINE INFECTION; IRRITABLE COLON; ISCHEMIC COLITIS; JAUNDICE; LACTOSE INTOLERANCE; LICENSING; LIFESTYLE; LIVER DISEASE; MALABSORPTION; META ANALYSIS; MICROSCOPIC COLITIS; NAUSEA; NUTRITIONAL INTOLERANCE; PARALYTIC ILEUS; PATHOPHYSIOLOGY; PATIENT COUNSELING; POSTOPERATIVE COMPLICATION; PRESCRIPTION; PSYCHOTHERAPY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STRESS; SUICIDAL BEHAVIOR; SUSTAINED DRUG RELEASE; SYMPTOM; TACHYCARDIA; TACHYPHYLAXIS; TREATMENT OUTCOME; URINE RETENTION; VIVID DREAM; XEROSTOMIA;

EID: 33746554943     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0015-6     Document Type: Review

References (45)

1. Thompson WG, Longstreth G, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. In Rome II: The Functional Gastrointestinal Disorders, edn 2. Edited by Drossman DA, Corazziari E, Talley NJ, et al. McLean, VA: Degnon Associates; 2000:351-432.
2. Drossman DA, Camilleri M, Mayer EA, Whitehead WE: AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123:2108-2131.
3. Schiller LR: Chronic diarrhea. Gastroenterology 2004, 127:287-293.
4. Camilleri M:AChronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist. Clin Gastroenterol Hepatol 2004, 2:198-206.
5. Fine KD, Schiller LR: AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999, 116:1464-1486.
6. Evaluation and management of chronic diarrhea: An algorithmic approach. http://www.medscape.com/viewprogram/4579_pnt. Accessed January 19, 2006.
7. Vanner SJ, Depew WT, Paterson WG, et al.: Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999, 94:2803-2807.
8. Tibble JA, Sigthorsson G, Foster R, Forgacs I: Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002, 123:450-460.
9. Adeniji OA, Barnett CB, DiPalma JA: Durability of the diagnosis of irritable bowel syndrome based on clinical criteria. Dig Dis Sci 2004, 49:572-574.
10. Cash BD, CIey WD: Review article: irritable bowel syndrome - an evidence-based approach to diagnosis. Aliment Pharmacol Ther 2004, 19:1235-1245.
11. Chassany O, Michaux A, Bergmann JF: Drug-induced diarrhoea. Drug Saf 2000, 22:53-72.
12. Farthing MJ: Functional diarrhea. Curr Gastroenterol Rep 2005, 7:350-357.
13. Bazzocchi G, Ellis J, Villanueva-Meyer J, et al.: Effect of eating on colonic motility and transit in patients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations. Gastroenterology 1991, 101: 1298-1306.
14. Charles F, Phillips SF, Camilleri M, Thomforde GM: Rapid gastric emptying in patients with functional diarrhea. Mayo Clin Proc 1997, 72:323-328.
15. Dunlop SP, Coleman NS, Blackshaw E, et al.: Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005, 3:349-357.
16. Gilkin RJ, Jr: The spectrum of irritAble bowel syndrome: a clinical review. Clin Ther 2005, 27:1696-1709.
17. Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002, 122:1140-1156.
18. Bercik P, Verdu EF, Collins SM: Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005, 34:235-245.
19. Gorard DA, Gomborone JE, Libby GW, Farthing MJ: Intestinal transit in anxiety and depression. Gut 1996, 39:551-555.
20. Palsson OS, Drossman DA: Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol Clin North Am 2005, 34:281-303.
21. Monsbakken KW, Vandvik PO, Farup PG: Perceived food intolerance in subjects with irritable bowel syndrome - etiology, prevalence and consequences. Eur J Clin Nutr 2005 [Epub ahead of print].
22. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ: Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial. Gut 2004, 53:1459-1464.
23. Zar S, Mincher L, Benson MJ, Kumar D: Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol 2005, 40:800-807.
24. Saito YA, Locke GR 3rd, Weaver AL, et al.: Diet and functional gastrointestinal disorders: A population-based case-control study. Am J Gastroenterol 2005, 100:2743-2748.
25. Kalliomaki MA: Food allergy and irritable bowel syndrome. Curr Opin Gastroenterol 2005, 21:708-711.
26. Bijkerk CJ, MTris JW, Knottnerus JA, et al.: Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 19:245-251.
27. Brandt LJ, Bjorkman D, Fennerty MB, et al.: Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(Suppl 11):S7-S26.
28. Scarlett Y. Medical management of fecal incontinence. Gastroenterology 2004, 126(Suppl 1):S55-S63.
29. Talley NJ: Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003, 98:750-758.
30. Lexi-Comp Online. http://www.lexi.com.lib-proxy.lib.unc.edu. Accessed February 11, 2006, for all medications discussed above.
31. Poynard T, Regimbeau C, Benhamou Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001, 15:355-361.
32. Baker DE: Rationale for using serotonergic agents to treat irritable bowel syndrome. Am J Health Syst Pharm 2005, 62:700-711.
33. Friedel D, Thomas R, Fisher RS: Ischemic colitis during treatment with alosetron. Gastroenterology 2001, 120:557-560.
34. Hyman PE, Garvey TQ, 3rd: Return of alosetron. Expert Opin Drug Saf 2002, 1:1-4.
35. Mayer EA, Bradesi S: Alosetron and irritable bowel syndrome. Expert Opin Pharmacother 2003, 4:2089-2098.
36. Cole JA, Cook SF, Sands BE, et al.: Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004, 99:486-491.
37. Chey WD, Chey WY, Heath AT, et al.: Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004, 99:2195-2203.
38. Andresen V, Hollerbach S: Reassessing the benefits and risks of alosetron: What is its place in the treatment of irritable bowel syndrome? Drug Saf 2004, 27:283-292.
39. Chey WDA Cash BD: Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin Investig Drugs 2005, 14:185-193.
40. Hearing SD, Thomas LA, Heaton KW, Hunt L: Effect of cholecystectomy on bowel function: A prospective, controlled study. Gut 1999, 45:889-894.
41. Jackson JL, O'Malley PG, Tomkins G: Treatment of functional gastrointestinal disorders with antidepressant medications: A meta-analysis. Am J Med 2000, 108:65-72.
42. Van Citters GW, Lin HC: Management of small intestinal bacterial overgrowth. Curr Gastroenterol Rep 2005, 7:317-320.
43. Sharara AI, Aoun E, Abdul-Baki H, et al.: A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006, 101:326-333.
44. Verdu EF, Collins SM: Irritable bowFl syndrome and probiotics: from rationale to clinical use. Curr Opin Gastroenterol 2005, 21:697-701.
45. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: A review of meta-analyses. Clin Psychol Rev 2006, 26:17-31.